Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The objective of this single-center clinical trial was to evaluate the objective response
rate and safety of Toripalimab combined with tyrosine kinase inhibitors TKI (Lenvatinib) in
neoadjuvant treatment of（T2a-T4NanyM0 or TanyN1M0） clear cell renal cell carcinoma.